Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bcee9c1eda8a50f22eb9732e0eb55531d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bcee9c1eda8a50f22eb9732e0eb55531d NCIT_P378 "NCI" @default.
- Bcee9c1eda8a50f22eb9732e0eb55531d type Axiom @default.
- Bcee9c1eda8a50f22eb9732e0eb55531d annotatedProperty IAO_0000115 @default.
- Bcee9c1eda8a50f22eb9732e0eb55531d annotatedSource NCIT_C156738 @default.
- Bcee9c1eda8a50f22eb9732e0eb55531d annotatedTarget "A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity." @default.